Applied Filters
UCB challenges Teva generic drug application
Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Merck wins injunction in sitagliptin patent row
Pharmaceutical company Merck has secured a preliminary injunction against Indian drug company Aprica after it tried to market generic versions of the branded diabetes drug Januvia.
Generics swoop as Viagra patent expires
Global drug companies Actavis and Teva both launched generic versions of Viagra immediately after its patent expired in several European countries last week.
Federal Circuit holds Novo Nordisk patent invalid
The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.
European Commission targets alleged ‘pay-for-delay’ with pharma fines
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.
US Supreme Court backs ‘rule-of-reason’ for pay-for-delay
A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Teva and Sun stung by $2 billion settlement
Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.
IPAB sets aside Sutent patent rejection
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
Shire settles with Teva over ADHD drug
Drug-maker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product, according to a patent settlement between the companies.
Takeda sues generics over heartburn drug
Japanese pharma company Takeda has sued generic drug-makers Impax and Sandoz for allegedly infringing a patent directed to its anti-heartburn drug Dexilant.
